Pfizer and anzhen launch the first cardiovascular medical big data center in China

Source: e-medicine Facebook on October 18, 2014, Beijing Anzhen Hospital Affiliated to Capital Medical University and Pfizer Investment Co., Ltd jointly signed a strategic cooperation project to launch the first cardiovascular medical big data center in China It is understood that the strategic cooperation plan lasts for 5 years Through the establishment of big data center, a new type of scientific research cooperation and exchange platform is established, which is a pioneering move for the medical industry to enter the era of big data At present, the common research methods to solve the clinical problems of cardiovascular disease mainly include randomized controlled study, observational study and cohort study These methods often have the disadvantages of single problem solving, long research cycle, huge cost of manpower and material resources "The practice of big data in the field of cardiovascular disease is not only a new attempt to solve various problems, but also an imperative trend." Professor Ma Changsheng, director of the Cardiology Center of Beijing Anzhen Hospital and President of the cardiology branch of the Chinese Association of physicians, said, "the application of big data will make guiding opinions and decision-making suggestions for improving the level of cardiovascular disease prevention and treatment, improve the level of medical research and diagnosis and treatment of cardiovascular disease in China, and benefit the majority of patients with cardiovascular disease." However, the current domestic health and disease database systems are usually relatively isolated How to integrate each data platform organically and use big data technology to develop and utilize it efficiently is what all the medical big data followers and participants think about "Integrating and combing data is the first step of our exploration," Professor Ma Changsheng said "For example, we plan to establish linkable data conversion, link interface and use rules based on the medical data of 4.7 million permanent residents in a certain urban area of Beijing, combined with the medical management information and medical insurance information of Beijing public health information center On this basis, we will gradually realize the links between cardiovascular disease databases, the continuous improvement and expansion of data sources, the maturity of service operation system and the application research on the basis of big data platform " It is understood that the big data application center provides evidence-based evidence for effective prevention and treatment of cardiovascular diseases with the help of big data analysis methods The center can also serve for comparative effect research, epidemiological monitoring and health policy-making of different cardiovascular diagnosis and treatment measures "In terms of operation mode, the center also integrates advantages from medical institutions, multinational pharmaceutical companies and other aspects of society It is reported that after the establishment of the center, a series of big data mining and analysis projects will be launched, including cardiovascular safety evaluation of commonly used clinical drugs, risk prediction model of cardiovascular disease, cardiovascular disease incidence, hospitalization and death monitoring, cardiovascular medical quality evaluation and feedback system establishment, cost-benefit analysis of cardiovascular disease diagnosis and treatment, etc